Products & Pipeline

We are developing and commercializing novel Digital Therapeutics for a variety of indications including smoking cessation, major depressive disorder, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity.

CT-100: Click Neurobehavioral Intervention (CNI) Platform

Product

Indication

Collaborator

Phase 1
Discovery

Phase 2
Dev/Pilot

Phase 3
Pivotal

Regulatory

Launch

Phase

CT-101
Clickotine®

Smoking Cessation

Launch

CT-152

Major Depressive Disorder (MDD)

Otsuka

Regulatory

CT-155

Schizophrenia

Boehringer Ingelheim

Pivotal

CT-132

Migraine

Pivotal

CT-156

Schizophrenia

Boehringer Ingelheim

Dev/Pilot

CT-102

Opioid Use Disorder (OUD)

Indivior

Discovery

CT-133

Multiple Sclerosis (MS)

Discovery

CT-171

Atopic Dermatitis

Discovery

CT-181

Obesity

Discovery

CT-191

Oncology

Discovery

CT-141
Clickadian™

Insomnia

Discovery

CT-111
Clickheart™

Acute Coronary Syndrome

Discovery

Clickotine®

CT-101

An all in one, comprehensive digital smoking cessation program

learn more

.product__StyledBackgroundImage-sc-7d572v-2.fCATDf:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/PHmAaqvbOHFxQdXqMcxLv/910e88d7a4e125ff29ca606c016f7096/product-list-image-1_cropped.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Major Depressive Disorder (MDD)

CT-152

Click is researching multiple cognitive exercises for the treatment of MDD.

.product__StyledBackgroundImage-sc-7d572v-2.ivPyXE:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/2MX4wXSJZcgKJxQvVff36A/f56af9339e5eeb6fad47a792d0853ed9/product-list-image-2.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Schizophrenia

CT-155

Confidential

.product__StyledBackgroundImage-sc-7d572v-2.ivPyXE.gbi--245564917-rYxjHCkGsYLNibojWTRisb:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/2293JGD1rwbBDZnfYxBd2n/c4d94c6f2d987e505e42463acae3d5ea/product-list-image-5.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Migraine

CT-132

Confidential

.product__StyledBackgroundImage-sc-7d572v-2.ivPyXE.gbi--607654308-apiUWAUQobnFVX7DEYqn26:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/5aLgG7oYzej2LOojtU46nM/ac4cc777b5c9f583df77659e00c82958/product-list-image-4.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Schizophrenia

CT-156

Confidential

.product__StyledBackgroundImage-sc-7d572v-2.ivPyXE.gbi-750044974-e56TgRbxsfM4JyCeG45qms:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/sec06H2Z5CZaUsnGq4QyL/0e2e7dda44c94c81e6fba20ac87daf89/product-list-image-8.jpg?w=1200&h=800&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Clickadian™

CT-141

Clickadian is under development as a clinically-validated fully digital program for insomnia

learn more

.product__StyledBackgroundImage-sc-7d572v-2.fCATDf.gbi-571670643-bmThqv7SkUaxJxyb3cqkD7:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/6cdcuVOYDUgaErfZqCQCkM/e184768856e8f8c2e74d2a63c96dbff5/product-list-image-3.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Clickheart™

CT-111

Clickheart is under development as a clinically-validated digital program for acute coronary syndrome

learn more

.product__StyledBackgroundImage-sc-7d572v-2.fCATDf.gbi--14835613-5eDjDL64THva9eV7jSdzGQ:before { opacity: 1; background-image: url(''https://images.ctfassets.net/2cin6yp65173/1DdlBGxlpMKQQpS6uGUGHz/bbb1ae0a4e3ac9025522ff72067a661e/product-list-image-6_cropped.jpg?w=1440&h=2052&fl=progressive&q=60&fm=jpg&bg=transparent''); }

Additional Products in Research & Development

CT-131

Chronic Lower
Back Pain

CT-161

Overactive
Bladder

CT-171

Atopic
Dermatitis

CT-181

Obesity

CT-191

Oncology

Chronic Kidney
Disease

Chronic Obstructive
Pulmonary Disease

Osteoarthritis

Products in development are investigational Digital Therapeutics not for sale. FDA has not yet evaluated the safety or effectiveness of these products.